Daniel J. Diekema

40.7k total citations · 10 hit papers
352 papers, 30.6k citations indexed

About

Daniel J. Diekema is a scholar working on Infectious Diseases, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, Daniel J. Diekema has authored 352 papers receiving a total of 30.6k indexed citations (citations by other indexed papers that have themselves been cited), including 271 papers in Infectious Diseases, 174 papers in Epidemiology and 80 papers in Clinical Biochemistry. Recurrent topics in Daniel J. Diekema's work include Antifungal resistance and susceptibility (144 papers), Fungal Infections and Studies (106 papers) and Antimicrobial Resistance in Staphylococcus (92 papers). Daniel J. Diekema is often cited by papers focused on Antifungal resistance and susceptibility (144 papers), Fungal Infections and Studies (106 papers) and Antimicrobial Resistance in Staphylococcus (92 papers). Daniel J. Diekema collaborates with scholars based in United States, Brazil and United Kingdom. Daniel J. Diekema's co-authors include Michael A. Pfaller, S. A. Messer, Ronald N. Jones, R. J. Hollis, L. Boyken, S. Tendolkar, Gary V. Doern, Loreen A. Herwaldt, J. Kroeger and Eli N. Perencevich and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Daniel J. Diekema

341 papers receiving 29.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

2007 3.2k citations Michael A. Pfaller, Daniel J. Diekema Clinical Microbiology Reviews profile →
Survey of Infections Due toStaphylococcusSpecies: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997–1999

2001 1.1k citations Daniel J. Diekema, Michael A. Pfaller et al. Clinical Infectious Diseases profile →
Attributable Mortality of Nosocomial Candidemia, Revisited

2003 918 citations S. A. Messer, Michael A. Pfaller et al. Clinical Infectious Diseases profile →
Epidemiology of Invasive Mycoses in North America

2010 711 citations Michael A. Pfaller, Daniel J. Diekema Critical Reviews in Microbiology profile →
Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016

2019 562 citations Michael A. Pfaller, Daniel J. Diekema et al. profile →
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion

2010 554 citations Michael A. Pfaller, Daniel J. Diekema et al. Journal of Clinical Microbiology profile →
Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyondCandida albicansandAspergillus fumigatus

2004 520 citations Michael A. Pfaller, Daniel J. Diekema Journal of Clinical Microbiology profile →
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program

2019 409 citations Daniel J. Diekema, Michael A. Pfaller et al. Antimicrobial Agents and Chemotherapy profile →
Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012

2012 392 citations Michael A. Pfaller, Daniel J. Diekema Journal of Clinical Microbiology profile →
Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008

2014 321 citations Michael A. Pfaller, Daniel J. Diekema et al. profile →

Peers

Countries citing papers authored by Daniel J. Diekema

Since Specialization

Citations

This map shows the geographic impact of Daniel J. Diekema's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Diekema with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Diekema more than expected).

Fields of papers citing papers by Daniel J. Diekema

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. Diekema. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Diekema. The network helps show where Daniel J. Diekema may publish in the future.

Co-authorship network of co-authors of Daniel J. Diekema

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. Diekema. A scholar is included among the top collaborators of Daniel J. Diekema based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. Diekema. Daniel J. Diekema is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Asymptomatic Testing of Hospital Admissions for SARS-CoV-2: Is it OK to Stop? 2023 ·Clinical Infectious Diseases ·(unknown), Takaaki Kobayashi, Daniel J. Diekema	6
2	What Is New in Fungal Infections? 2023 ·Modern Pathology ·(unknown), Daniel J. Diekema	13
3	Changes in Pneumococcal Serotypes and Antimicrobial Resistance after Introduction of the 13-Valent Conjugate Vaccine in the United States 2014 ·Antimicrobial Agents and Chemotherapy ·Sandra S. Richter, Daniel J. Diekema, Kristopher P. Heilmann, Cassie L. Dohrn, Fathollah Riahi, Gary V. Doern	129
4	Multicenter Comparison of the Vitek 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Caspofungin, Micafungin, and Posaconazole against Candida spp 2011 ·Journal of Clinical Microbiology ·Jess F. Peterson, Michael A. Pfaller, Daniel J. Diekema, Michael G. Rinaldi, Katherine M. Riebe, Nathan A. Ledeboer	26
5	Epidemiology of Invasive Mycoses in North America breakdown → 2010 ·Critical Reviews in Microbiology ·Michael A. Pfaller, Daniel J. Diekema	711
6	Screening of a Large Global Aspergillus fumigatus Species Complex Collection by Using a Species-Specific Microsphere-Based Luminex Assay 2009 ·Journal of Clinical Microbiology ·Kizee A. Etienne, Lalitha Gade, Shawn R. Lockhart, Daniel J. Diekema, S. A. Messer, Michael A. Pfaller, S. Arunmozhi Balajee	13
7	In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species 2008 ·Journal of Clinical Microbiology ·Michael A. Pfaller, S. A. Messer, L. Boyken, Charles V. Rice, S. Tendolkar, R. J. Hollis, Daniel J. Diekema	96
8	Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance Program 2008 ·Journal of Clinical Microbiology ·Michael A. Pfaller, L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, Daniel J. Diekema	39
9	Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin 2008 ·Journal of Clinical Microbiology ·Michael A. Pfaller, Vishnu Chaturvedi, Daniel J. Diekema, Mahmoud A. Ghannoum, (unknown), S. B. Killian, C C Knapp, S. A. Messer, (unknown), Rama Ramani	50
10	Antimicrobial Resistance among Gram-Negative Bacilli Causing Infections in Intensive Care Unit Patients in the United States between 1993 and 2004 2007 ·Journal of Clinical Microbiology ·Shawn R. Lockhart, Murray A. Abramson, Susan E. Beekmann, G. Gallagher, Stefan Riedel, Daniel J. Diekema, John P. Quinn, Gary V. Doern	309
11	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing 2007 ·Journal of Clinical Microbiology ·Michael A. Pfaller, Daniel J. Diekema, David L. Gibbs, V. A. Newell, Jacques F. Meis, I.M. Gould, Fu Wang, Arnaldo Lopes Colombo, Eduardo Rodríguez-Noriega	213
12	In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance 2007 ·Journal of Clinical Microbiology ·Michael A. Pfaller, L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, Daniel J. Diekema	320
13	Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem breakdown → 2007 ·Clinical Microbiology Reviews ·Michael A. Pfaller, Daniel J. Diekema	3211
14	Multicenter Comparison of the VITEK 2 Yeast Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp 2007 ·Journal of Clinical Microbiology ·Michael A. Pfaller, Daniel J. Diekema, Gary W. Procop, Michael G. Rinaldi	57
15	Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp 2006 ·Journal of Clinical Microbiology ·S. A. Messer, Daniel J. Diekema, L. Boyken, S. Tendolkar, R. J. Hollis, Michael A. Pfaller	88
16	In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance 2006 ·Journal of Clinical Microbiology ·Michael A. Pfaller, L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, Daniel J. Diekema	158
17	Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods 2006 ·Journal of Clinical Microbiology ·Michael A. Pfaller, S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, Daniel J. Diekema	69
18	Activities of Available and Investigational Antifungal Agents against Rhodotorula Species 2005 ·Journal of Clinical Microbiology ·Daniel J. Diekema, (unknown), S. A. Messer, R. J. Hollis, Michael A. Pfaller	89
19	Results from the ARTEMIS DISK Global AntifungalSurveillance Study: a 6.5-Year Analysis of Susceptibilitiesof Candida and Other Yeast Species to Fluconazole andVoriconazole by Standardized Disk Diffusion Testing 2005 ·Journal of Clinical Microbiology ·Michael A. Pfaller, Daniel J. Diekema, Michael G. Rinaldi, R.A. Barnes, Bijie Hu, Alexander V. Veselov, (unknown), E. Nagy, David L. Gibbs	186
20	Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program 2005 ·Journal of Clinical Microbiology ·Michael A. Pfaller, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, Daniel J. Diekema	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact